ReviewCurrent heart failure reports2026
Clonal Hematopoiesis and Inflammatory Pathways in Heart Failure with Preserved Ejection Fraction.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewThis review aims to examine the role of clonal hematopoiesis of indeterminate potential (CHIP) in the pathophysiology of heart failure with preserved ejection fraction (HFpEF), focusing on its contribution to inflammation, disease development, and clinical implications. RECENT
findingsRecent studies demonstrate that CHIP is enriched in HFpEF populations and is associated with increased disease risk and worse clinical outcomes. Mechanistically, CHIP promotes inflammatory signaling through activation of pathways such as the NLRP3 inflammasome and IL-1β/IL-6 axis. TET2 mutations, in particular, have been consistently linked to diastolic dysfunction and adverse remodeling, especially in patients with high inflammatory burden and cardiometabolic comorbidities. CHIP represents a novel link between ageing, inflammation, and HFpEF, contributing to disease heterogeneity and progression. It may serve as a biomarker for early detection, risk stratification, and patient phenotyping, while also offering potential therapeutic targets. Future research should focus on validating these findings and integrating CHIP into precision medicine approaches for HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.